Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Resolving PI3K-δ inhibitor resistance in CLL.

Klein U.

Blood. 2019 Aug 8;134(6):496-498. doi: 10.1182/blood.2019001177. No abstract available.

PMID:
31395581
2.

Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.

Göckeritz E, Kerwien S, Baumann M, Wigger M, Vondey V, Neumann L, Landwehr T, Wendtner CM, Klein C, Liu N, Hallek M, Frenzel LP, Krause G.

Int J Cancer. 2015 Nov 1;137(9):2234-42. doi: 10.1002/ijc.29579. Epub 2015 May 12.

3.

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.

Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, Jones J, Andritsos L, Puri KD, Lannutti BJ, Giese NA, Zhang X, Wei L, Byrd JC, Johnson AJ.

Blood. 2010 Sep 23;116(12):2078-88. doi: 10.1182/blood-2010-02-271171. Epub 2010 Jun 3.

4.

GS-1101: a delta-specific PI3K inhibitor in chronic lymphocytic leukemia.

Macias-Perez IM, Flinn IW.

Curr Hematol Malig Rep. 2013 Mar;8(1):22-7. doi: 10.1007/s11899-012-0142-1. Review.

PMID:
23114654
5.

PI3K-δ inhibitor produces long-lasting responses.

[No authors listed]

Cancer Discov. 2013 Jul;3(7):OF11. doi: 10.1158/2159-8290.CD-NB2013-075. Epub 2013 May 23.

6.

Idelalisib.

Zirlik K, Veelken H.

Recent Results Cancer Res. 2018;212:243-264. doi: 10.1007/978-3-319-91439-8_12. Review.

PMID:
30069634
7.

The PI3K pathway: clinical inhibition in chronic lymphocytic leukemia.

Brown JR.

Semin Oncol. 2016 Apr;43(2):260-4. doi: 10.1053/j.seminoncol.2016.02.004. Epub 2016 Feb 8. Review.

PMID:
27040704
8.

Idelalisib: First-in-Class PI3K Delta Inhibitor for the Treatment of Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia, and Follicular Lymphoma.

Yang Q, Modi P, Newcomb T, Quéva C, Gandhi V.

Clin Cancer Res. 2015 Apr 1;21(7):1537-42. doi: 10.1158/1078-0432.CCR-14-2034. Epub 2015 Feb 10. Review.

9.

Idelalisib and caffeine reduce suppression of T cell responses mediated by activated chronic lymphocytic leukemia cells.

Hock BD, MacPherson SA, McKenzie JL.

PLoS One. 2017 Mar 3;12(3):e0172858. doi: 10.1371/journal.pone.0172858. eCollection 2017.

10.

The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.

Crassini K, Shen Y, O'Dwyer M, O'Neill M, Christopherson R, Mulligan S, Best OG.

Br J Haematol. 2018 Sep;182(5):654-669. doi: 10.1111/bjh.15447. Epub 2018 Jul 5.

PMID:
29978459
11.

Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.

Barrientos JC.

Future Oncol. 2016 Sep;12(18):2077-94. doi: 10.2217/fon-2016-0003. Epub 2016 Jun 21. Review.

PMID:
27324214
12.

The pan phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor SAR245409 (voxtalisib/XL765) blocks survival, adhesion and proliferation of primary chronic lymphocytic leukemia cells.

Thijssen R, Ter Burg J, van Bochove GG, de Rooij MF, Kuil A, Jansen MH, Kuijpers TW, Baars JW, Virone-Oddos A, Spaargaren M, Egile C, van Oers MH, Eldering E, Kersten MJ, Kater AP.

Leukemia. 2016 Feb;30(2):337-45. doi: 10.1038/leu.2015.241. Epub 2015 Sep 4. Erratum in: Leukemia. 2016 Sep;30(9):1963.

PMID:
26338274
13.

The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.

Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, Zhang X, Lannutti BJ, Puri KD, Muthusamy N, Byrd JC, Johnson AJ.

Blood. 2011 Apr 21;117(16):4323-7. doi: 10.1182/blood-2010-11-315705. Epub 2011 Mar 4.

14.

The PI3-kinase delta inhibitor idelalisib (GS-1101) targets integrin-mediated adhesion of chronic lymphocytic leukemia (CLL) cell to endothelial and marrow stromal cells.

Fiorcari S, Brown WS, McIntyre BW, Estrov Z, Maffei R, O'Brien S, Sivina M, Hoellenriegel J, Wierda WG, Keating MJ, Ding W, Kay NE, Lannutti BJ, Marasca R, Burger JA.

PLoS One. 2013 Dec 23;8(12):e83830. doi: 10.1371/journal.pone.0083830. eCollection 2013.

15.

Targeted therapy in chronic lymphocytic leukemia: past, present, and future.

Danilov AV.

Clin Ther. 2013 Sep;35(9):1258-70. doi: 10.1016/j.clinthera.2013.08.004. Review.

16.

Bone marrow stroma-induced resistance of chronic lymphocytic leukemia cells to arsenic trioxide involves Mcl-1 upregulation and is overcome by inhibiting the PI3Kδ or PKCβ signaling pathways.

Amigo-Jiménez I, Bailón E, Aguilera-Montilla N, Terol MJ, García-Marco JA, García-Pardo A.

Oncotarget. 2015 Dec 29;6(42):44832-48. doi: 10.18632/oncotarget.6265.

17.

The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 (Duvelisib), overcomes signals from the PI3K/AKT/S6 pathway and promotes apoptosis in CLL.

Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V.

Leukemia. 2015 Sep;29(9):1811-22. doi: 10.1038/leu.2015.105. Epub 2015 Apr 28.

18.

Towards targeted therapy of chronic lymphocytic leukemia.

Niemann CU, Jones J, Wiestner A.

Adv Exp Med Biol. 2013;792:259-91. doi: 10.1007/978-1-4614-8051-8_12. Review.

PMID:
24014301
19.
20.

Supplemental Content

Support Center